Khiron receives its largest European medical cannabis shipment to date
Khiron's largest shipment to date of EU-GMP certified medical cannabis product arrives in Germany
Khiron 20/1, a THC-dominant Cannabis flower, becomes second Khiron-branded product to launch in Germany, having been prescribed in the UK
36.6kg shipment expected to have positive impact on Q2 2021 medical cannabis sales in Europe
German medical cannabis market positioned for significant growth with national insurance coverage and an estimated patient base of over 100,000
TORONTO, June 8, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the receipt of the Company's largest ever shipment of EU-GMP certified medical cannabis product for distribution and sale into the German market.
Recently, Khiron's German distribution partner, Nimbus Health GmbH, received approximately 36kg of Khiron 20/1 medical cannabis product, a THC-dominant cannabis flower product which has been prescribed to patients in the UK since July 2020. The new product increases the Company's German medical cannabis offering, which now includes both THC-dominant and CBD-dominant Cannabis products. As a result of the shipment, the Company expects to increase its European medical cannabis sales in the second quarter of 2021.
"As we launch another new product into Germany and more than triple our shipment volumes, our European team continues to demonstrate strong execution and leadership. In line with our Mission of improving patients' lives through medical cannabis, we continue to expand our offering of EU-GMP cannabinoid-based medicines. Simultaneously, we are developing additional products based on our Colombian extracts, whose efficacy and safety are backed by real-world evidence from over 20,000 prescriptions," comments Alvaro Torres, CEO and Director.
Khiron's European product portfolio now includes both THC-dominant and CBD-dominant cannabis flower products available for sale in Germany and the UK, two of the largest chronic pain markets in Europe. Over the coming months, the Company plans to increase patient access by expanding its product offering and medical education initiatives.
About Khiron Life Sciences Corp. Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany and the UK, and is positioned to commence sales in Mexico and Brazil in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
St. Joseph’s Health Centre turns 100: Builds first post COVID Emergency Department in country
Promise 100 campaign to ensure health care needs of west-end for next 100 years
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- St. Joseph’s Health Centre turns 100 this year and its Foundation is honouring a century of care by launching Promise 100, a campaign to ensure the hospital meets the health care needs of the west-end for the next century.
The campaign will support St. Joe’s community and health care providers through the following activities:
Building the first post COVID Emergency Department in the country and equipping it with critical equipment and technology.
Updating dedicated spaces for our physicians and staff to thank them for 100 years of care.
A century of care: From pandemic to pandemic 100 years ago, a group of caring and determined women saw a need in Toronto’s west-end community and stepped up to fill it. The Sisters of St. Joseph – an order of nuns who came to the city to help with a diphtheria epidemic in 1851 – founded St. Joseph’s Health Centre in 1921. They made a Promise to look after the health needs of Toronto’s west-end community and 100 years later that Promise is stronger than ever.
“We’ve seen that emergency care has been at the centre of the pandemic,” said Maria Dyck, President and CEO of St. Joseph’s Health Centre Foundation. “People living in the west-end of the city visit the Emergency Department at St. Joe’s more than 100,000 times each year, making it a vital community resource and one of the busiest emergency departments in the GTA. And while we offer excellent care, we do so in a space built for almost half the number of people who need us.”
Safe spaces for frontline personnel to fight pandemic The Promise 100 campaign will focus on ensuring the hospital and its dedicated health care teams can continue to fight the pandemic. Funds raised will expand the emergency department and update dedicated spaces for physicians and staff to have quiet time away from clinical areas, recognizing the emotional stress and burnout the pandemic is causing.
From humble beginnings St. Joe’s had 25 beds when it was founded by the Sisters in 1921. Today, it remains at the heart of Toronto’s west-end community. There are now more than 500,000 people living in this catchment area and St. Joe’s is one of Canada’s largest community teaching hospitals with almost 450 beds and over 400,000 visits annually.
Dr. Tim Rutledge, President and CEO of Unity Health Toronto (St. Joseph’s Health Centre, St. Michael’s Hospital and Providence Healthcare) says there has never been a time when community has mattered more. “It has been a challenging year, but we look to 2021 with hope and gratitude. Our teams have worked tirelessly to care for this community,” he says. “It’s inspiring to see donors and neighbours come together to help. Now we ask our neighbours to join us again in honouring 100 years of care by supporting emergency care and those on the frontlines.”
Simon Nyilassy, Chair of St. Joseph’s Health Centre Foundation Board of Directors, says he has seen the impact of donations on patient care at St. Joe’s. “Many Donors give because they’ve experienced care at St. Joseph's. West enders’ children and grandchildren were born here at St. Joe’s. They have had emergency or other care here, brought their children to us when they were ill or have had loved ones pass away at the end of their lives,” Nyilassy said. “This lifetime of care has prompted an outpouring of support in these challenging times and we hope it will continue so we can be here for 100 years more.”
The power of our community hospital As much as 80 per cent of people’s healthcare needs are supported by their community hospital. Many of the major points in people’s lives will happen right here: being born, giving birth, minor accidents and sicknesses growing up, major sickness and end of life.
How to help Westenders and all Canadians can learn more about the Promise 100 campaign and how to make a secure online donation to help St. Joe’s keep the Promise at www.supportstjoes.ca.
About St. Joseph’s Health Centre St. Joseph’s Health Centre, a strong partner within Unity Health Toronto, is a Catholic community teaching hospital affiliated with the University of Toronto that has served the communities of west Toronto and beyond since its founding by the Sisters of St. Joseph nearly a century ago. Empowered by the dedication of our staff, physicians, students and volunteers, and emboldened through strong partnerships and the input of local residents, St. Joseph’s is committed to achieving its vision of advancing the health of our community by being Canada’s best community teaching health centre. For more information on St. Joseph’s Health Centre, visit www.stjoestoronto.ca and for details on the Promise 100 campaign, go to www.supportstjoes.ca.
Being involved in a car accident can leave you dealing with various injuries. Some of these may be significant and require a medical evaluation and professional treatment. Here are some things you can do to get back to normal as quickly as possible.
Schedule a Medical Exam
See your regular medical doctor for a thorough examination and evaluation. Get a complete diagnosis of your injuries as well as recommended follow-up. Follow the doctor's orders regarding rest, medication, nutrition, and returning to work or regular activities. Your doctor can provide a thorough assessment of your injuries and estimated recovery time. You may need to be seen more than once for the doctor to monitor your progress and adjust the treatment plan if needed.
Follow Up With Prescribed Tests and Treatments
If the medical team has made referrals to specialists or suggested specific tests or treatments, follow through for a complete checkup. It is better to find out now about any hidden injuries and to have even those that seem minor checked out by medical experts. Missing a test or failing to take treatments now could make the problem worse and require more stringent and costly treatments later. If you must miss an appointment, reschedule it as soon as possible.
Resume Moderate Activities as Recommended
The medical practitioners you have consulted can advise you on the best way to recover quickly from your accident injuries. They may prescribe temporary rest or physical therapy. They will likely be able to recommend specific exercises you can do at home to speed your recovery. A healthy diet may likewise be suggested. Don't overdo it even if you feel much better in a few days. Trying to do too much, too soon, can lead to relapse and undo all the positive effects to date. Follow the prescribed routine to heal completely.
Consult a Chiropractor as Needed
The doctor might mention the option of consulting a chiropractor for additional treatment of your car accident injuries. The chiropractor can maneuver your limbs and torso to reduce tension and increase flexibility while suggesting things you can do on your own to get back to normal movement. Look for an accident chiropractor who specializes in treating the kinds of injuries you may be dealing with following a vehicle collision.
A car accident often requires the help of experts and professionals to help you recover. Take advantage of the resources available that can expedite your recovery from your accident injuries.
How to Be More Relaxed Building Up to Your First Big Race
Planning to compete in a race is an exciting, enthralling experience; however, you're also likely feeling a bit nervous, especially since it's your first time. While a little bit of nervous anticipation can help drive you to success, you also do not want to become overwhelmed with fear and anxiety. Employing some relaxing strategies can help you to take it easy.
Turn to Meditative Practices
Learning how to meditate or engage in similar activities can assist you in staying grounded, focused and calm. Whether you choose a secular meditation class, a private meditation at home or prayer at a house of worship, these practices allow you to connect with yourself and with a greater good. Consider starting off your day with meditation or prayer to begin the morning in a relaxed state. As you get close to race day, consider when you might have a moment to meditate before putting on your running shoes.
Maintain a Schedule
When race day is rapidly approaching, you might want to spend every waking moment preparing for the competition. However, constantly thinking about the race isn't healthy. While it's true that you may need to increase your training, you need to keep your schedule open for other activities as well. For example, you should still go to work, engage in your other hobbies and socialize with loved ones. You need to keep a healthy balance in order to decompress and avoid filling your mind with only thoughts of the race.
Adjust Your Intake
In order to determine precisely how you should adjust your food and liquid intake before a race, you need to speak with a medical professional. People have different needs based on their bodies, schedules and other factors. You might, for example, learn that taking full spectrum CBD gummies can help you to stay calm as the race approaches. These types of gummies often improve sleep, help calm nerves, and can ease anxiety when taken on a regular basis. On the other hand, you may discover that certain foods that you're consuming regularly are leading to an increase in anxiety.
Express Your Fears
Working to minimize stress is important and useful, but you also cannot simply deny the way that you are feeling. Expressing your worries and concerns is a healthy practice, and you can accomplish this goal in a number of ways. You may want to write or draw what you are feeling. If you find that the anxiety is taking over your life, consider speaking with a therapist.
Allow yourself to feel excitement about your first big race. However, do not ignore the feelings of worry and anxiety that you have. Address these emotions as well.
First new treatment for Alzheimer's disease approved in nearly two decades offers hope for people living with dementia
Alzheimer Society of Canada calls for more investment in dementia research
TORONTO, June 7, 2021 /CNW/ - The Alzheimer Society of Canada is hopeful about the U.S. Food and Drug Administration's (FDA) approval of aducanumab, a new treatment for Alzheimer's disease. This news represents an important step forward for people living with Alzheimer's disease. The FDA requires that Biogen complete an additional clinical trial to verify the drug's benefit. If the trial fails to verify the clinical benefit, the FDA may initiate proceedings to withdraw approval. For aducanumab to be available in Canada, the drug will require regulatory approval by Health Canada to ensure its safety and efficacy. The Alzheimer Society of Canada is urging Health Canada to complete its required reviews swiftly, while maintaining the highest safety standards, so that aducanumab can be made available as quickly as possible to people living with dementia in Canada.
While this approval is encouraging, aducanumab is not suitable for all people at all stages of dementia. The drug may slow the decline in cognitive skills and functional ability in people living with Mild Cognitive Impairment (MCI) or in the early stages of Alzheimer's disease. Aducanumab is reported to work by clearing harmful amyloid beta that builds up in the brain, which is thought to result in Alzheimer's disease.
"Over the next 10 years, we anticipate that more than one million people in Canada will be living with dementia. The approval of aducanumab underscores how investing in research can lead to better treatment options, but the drug is just one treatment," says Dr. Saskia Sivananthan, Chief Science Officer, Alzheimer Society of Canada. "Research for Alzheimer's disease and other dementias is significantly under-funded when compared to other diseases. There is an urgent need to invest in dementia research to provide people living with the disease new and better treatments. Most importantly, research investment is crucial to finding cures for Alzheimer's disease and other dementias."
The Alzheimer Society of Canada is committed to funding innovative dementia research focused on prevention, diagnosis, treatment, and finding cures for Alzheimer's disease and other dementias. To learn more, visit www.alzheimer.ca.
About the Alzheimer Society
The Alzheimer Society is Canada's leading nationwide health charity for people living with Alzheimer's disease and other dementias. Active in communities across Canada, the Society provides information, programs and services to those living with a diagnosis and their caregivers. The Alzheimer Society Research Program is Canada's leading funder of research into better understanding the causes of dementia, improving treatment and care, and towards finding cures.
SOURCE Alzheimer Society of Canada
Celltrion Healthcare launches Remsima™ SC, the world's first subcutaneous formulation of infliximab in Canada, for the treatment of people with rheumatoid arthritis
Remsima™ SC offers an innovative treatment option for patients living with chronic inflammatory conditions in Canada
Remsima™ SC is supported by the CELLTRION CONNECT™ Patient Support Program
Celltrion Healthcare Canada Limited aims to expand access to innovative and high-quality biologics
TORONTO, June 7, 2021 /CNW/ - Celltrion Healthcare Canada Limited announced today the launch of Remsima™ SC (CT-P13 SC), the world's first subcutaneous formulation of infliximab in Canada for the treatment of adult patients with rheumatoid arthritis (RA). Health Canada granted a notice of compliance (NOC) for Remsima™ SC in Canada for the treatment of adult patients with rheumatoid arthritis (RA) on January 28.1
"We are delighted to be able to launch Remsima™ SC today and to bring the first and only subcutaneous form of infliximab to patients, payers and clinicians in Canada," said Jovan Antunovic, Commercial Director at Celltrion Healthcare Canada. "Our team is strong, growing and proud that Remsima™ SC will be the first product to be commercially available in the Canadian market under our new direct sales marketing strategy and is supported by the comprehensive CELLTRION CONNECT™ patient support program. We will continue to enhance our presence in Canada by collaborating with the different stakeholders to support the company's growth strategy."
Remsima™ SC is commercially available in Canada in 120 mg fixed dose as a pre-filled pen (auto-injector) and is administered as a bi-weekly subcutaneous injection. It is approved in Canada for use in combination with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage and improvement in physical function in adult patients with moderately to severely active rheumatoid arthritis and should be used as maintenance therapy after the completion of an induction period with intravenous infliximab.2
"Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that can lead to irreparable joint destruction if not properly treated," said Professor Edward Keystone, Professor of Medicine, University of Toronto, Toronto, Canada. "Having a subcutaneous formulation of infliximab means patients can have a more flexible dosing schedule and control on how they receive their treatment."
The approval was based on clinical evidence including results from a study that showed switching people with RA from the intravenous (IV) formulation to the SC formulation of CT-P13 treatment at Week 30 was comparable to maintaining CT-P13 SC up to Week 54 (up to Week 64 for safety profile).2,3
Notes to Editors:
About CELLTRION CONNECT™ Patient Support Program
CELLTRION CONNECT™ patient support program is designed to support patients, caregivers, and healthcare providers with access to Remsima™ SC. Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/
About CT-P13 (biosimilar infliximab)4, 5, 6
CT-P13 is developed and manufactured by Celltrion, Inc. and was the world's first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including RA and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The U.S. Food and Drug Administration approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 94 countries (as of June 2021) including the US, Canada, Japan and throughout Europe.
CT-P13 IV is usually given as 3 mg per kg/body weight in RA and as 5 mg per kg/body weight for the other indications. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards. The subcutaneous (SC) formulation has the potential to enhance treatment options for the use of infliximab biosimilar by providing high consistency in drug exposure and a convenient method of administration.
CT-P13 SC has received EU marketing authorization for the treatment of people with RA and IBD in November 2019 and July 2020, respectively. In the United States, Remsima® SC will be reviewed through the new drug pathway by the U.S. Food and Drug Administration (FDA) with the outcome expected by 2022.
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients' access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the U.S. FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com/en-us
Westhovens R et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology (Oxford) 2020 Nov 23;keaa580: doi: 10.1093/rheumatology/keaa580.
Yoo DH, Jaworski J, Matyska-Piekarska E et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: One-year results from part one of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (FRI0128). Presented at EULAR 2019.
6.
Westhovens R, Wiland P, Zawadzki M et al. A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 30-week results from part two of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis. Poster (SAT0170). Presented at EULAR 2019.
SOURCE Celltrion Healthcare
Health Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
Approval supported by efficacy and safety data of two pivotal Phase 3 studies in which RINVOQ demonstrated improved joint outcomes, physical function and skin symptoms, with a greater proportion of patients achieving minimal disease activity versus placebo* 1,2
Significantly more patients taking RINVOQ achieved an ACR20 response than patients receiving placebo 1,2
MONTREAL, June 7, 2021 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved RINVOQ® (upadacitinib, 15 mg), an oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other Disease-Modifying Anti-Rheumatic Drugs (DMARDs).3
"Psoriatic arthritis is a debilitating disease that can cause severe pain, restricted mobility, and lasting structural damage.4, 5 The immune system creates inflammation that can lead to skin lesions associated with psoriasis, as well as pain, fatigue and stiffness in the joints," 6,7 said Dr. Proton Rahman, FRCPC, Clinical Rheumatologist at Eastern Health and University Research Professor at Memorial University. "Despite treatment advances, some people living with PsA do not achieve their treatment goals, which is why access to new therapies is so critical. The approval of RINVOQ offers Canadian physicians and their patients an important new therapeutic option."
"I have had psoriatic arthritis and psoriasis for more than 30 years. At one point, most of my body was covered in psoriasis, and I was using arm and leg braces to help me walk. These diseases have had a huge impact on my life, which is why I am so pleased that Canadians with psoriatic arthritis now have a new treatment option available to them," said Marilyn Porth, of Winnipeg, Manitoba.
This approval is supported by data from two Phase 3 studies across a broad range of more than 2,000 patients with active psoriatic arthritis.1,2 In both studies, RINVOQ met the primary endpoint of ACR20 response at week 12 versus placebo.1,2RINVOQ 15 mg also achieved non-inferiority versus adalimumab in terms of ACR20 response at week 12.1 Patients receiving RINVOQ also experienced greater improvements in physical function (HAQ-DI*) and skin symptoms (PASI 75*), and a greater proportion achieved minimal disease activity.1,2 Overall, the safety profile of RINVOQ in psoriatic arthritis was consistent with previously reported results across the Phase 3 rheumatoid arthritis clinical trial program, with no new significant safety risks detected.1,2,8
"The approval of RINVOQ is wonderful news for Canadians living with psoriatic arthritis, and an important step forward for the psoriatic arthritis community," says Wendy Gerhart, Executive Director, Canadian Spondylitis Association. "From our recent member surveys, we know this devastating disease has a profound impact on people's quality of life including their physical and mental health. This approval provides a new treatment option to Canadian patients. It is a hopeful time for people living with psoriatic arthritis."
"For more than 20 years, AbbVie has been dedicated to discovering and delivering innovative therapies for people living with rheumatic diseases," added Tracey Ramsay, Vice President and General Manager, AbbVie Canada. "We are proud of our deep heritage in rheumatology and pleased to expand our portfolio of treatment options for Canadians living with psoriatic arthritis, particularly by offering people the convenience of a once-daily oral medication."
*Physical function was measured by the Health Assessment Questionnaire Disability Index (HAQ-DI). Skin symptoms were measured by a 75 percent improvement in the Psoriasis Area and Severity Index (PASI 75). Minimal disease activity is defined as the fulfillment of five of seven outcome measures: Tender joint count ≤1; swollen joint count ≤1; PASI ≤1 or body surface area-psoriasis ≤3 percent; Patient's Assessment of Pain Numerical Rating Scale (NRS) ≤1.5; Patient Global Assessment-Disease Activity NRS ≤2.0; HAQ-DI score ≤0.5; and Leeds Enthesitis Index ≤1.
About SELECT-PsA 1 1,3
SELECT-PsA 1 is a Phase 3, multicenter, randomized, double-blind, parallel-group, active and placebo-controlled study designed to evaluate the safety and efficacy of upadacitinib compared to placebo and adalimumab in adult patients with active psoriatic arthritis who have a history of inadequate response to at least one non-biologic DMARD.
Top-line results from SELECT-PsA 1 were previously announced in February 2020. More information on this trial can be found at www.clinicaltrials.gov (NCT03104400).
About SELECT-PsA 2 2,3
SELECT-PsA 2 is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study designed to evaluate the safety and efficacy of RINVOQ in adult patients with active psoriatic arthritis who have a history of inadequate response to at least one biologic DMARD.
Top-line results from SELECT-PsA 2 were previously announced in October 2019. More information on this trial can be found at www.clinicaltrials.gov (NCT03104374).
About RINVOQ®(upadacitinib)
RINVOQ is a 15 mg, once-daily oral medication in an extended-release tablet. It is a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway, which is thought to play a role in inflammatory response.
RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate, as well as for adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs. In RA, RINVOQ may be used as a monotherapy or in combination with methotrexate or other nonbiologic DMARDs. In PsA, RINVOQ may be used as a monotherapy or in combination with methotrexate.
For important safety information, please consult the RINVOQ Product Monograph at www.abbvie.ca.
About AbbVie in Rheumatology
For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering innovative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca. Follow @abbviecanada on Twitter or find us on Facebook, Instagram, YouTube and LinkedIn.
References
1.
McInnes I, et al. Efficacy and Safety of Upadacitinib Versus Placebo and Adalimumab in Patients With Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-1): a Double-Blind, Randomized Controlled Phase 3 Trial. 2020 EULAR E-Congress; LB0001.
2.
Genovese MC, et al. Efficacy and Safety of Upadacitinib in Patients With Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-PsA-2): a Double-Blind, Randomized Controlled Phase 3 Trial. 2020 EULAR E-Congress; OP0223.
Schett G, et al. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res & Ther.2011; 13(Suppl1) :s4(1-9)
6.
uarte GV, et al. Psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012 Feb;26(1):147-56. doi: 10.1016/j.berh.2012.01.003.
Cohen S., et al. Safety profile of upadacitinib in Rheumatoid Arthritis: Integrated analysis from the SELECT Phase 3 Clinical Program. EULAR 2019; THU0167.
SOURCE AbbVie Canada
On World Oceans Day, Oceana Canada calls on Feds to Put Wild Fish First in Developing a Blue Economy Strategy
Only ¼ of our Fisheries are Healthy; 97% of Canadians Want the Government to Rebuild Them
TORONTO, June 07, 2021 (GLOBE NEWSWIRE) -- On the eve of World Oceans Day, new polling1 released today from Oceana Canada finds that an overwhelming majority of Canadians care deeply about healthy oceans and protecting wild fish populations: 97 per cent say it is important that the Canadian government work to rebuild fish populations to healthy levels, and 95 per cent of all Canadians — 99 per cent of Atlantic Canadians — say it is an important part of our post-pandemic economic recovery.
Canada has not kept pace with progressive fishing nations in correcting the historic mistake of overfishing by allowing fish populations to rebuild, thus creating healthier ecosystems, more jobs, food and income, and opportunities to practice cultural traditions. However, right now, there is a once-in-a-generation opportunity to fix this. Fisheries and Oceans Canada is asking for input before June 15, 2021, to help shape its Blue Economy Strategy that aims to make the oceans healthy and prosperous as part of Canada’s plan to ‘build back better’ from the economic and social havoc wreaked by the global COVID-19 pandemic.
In the face of the global pandemic and environmental threats from climate change, plastic pollution, overfishing and habitat destruction, the need to protect and restore our oceans has never been more urgent. However, most of the historically bountiful wild fish populations we have relied on for food, jobs, income, culture and recreation have been collapsed for decades or are declining due to overfishing and mismanagement. Only a quarter of Canada’s fisheries are healthy.
“The original foundation of Canada’s ‘blue economy’ has always been our most plentiful and naturally renewing resource: wild fish – which today support the largest job, income and revenue-generating sector within Canada’s ocean-based economy,” said Josh Laughren, Executive Director, Oceana Canada. “Rebuilding fish to healthy, abundant levels must be central to any blue economy strategy, for our oceans and for all the people that rely on them.”
“For Prime Minister Justin Trudeau and Fisheries Minister Bernadette Jordan, this is a once-in-a-generation opportunity. Canada can be a leader with a regenerative blue economy strategy that is the envy of the world, but only if it prioritizes our oceans’ most renewable resource. Without wild fish, there is no blue economy,” said Laughren. “We urge the many Canadians who care so passionately about this issue to join us and call on the government to deliver on its promise to rebuild Canada’s once world-class fisheries, which we have systematically depleted over the past century, for the sake of all those who rely on it today and as a moral obligation to future generations,” said Laughren.
“The good news is that the government already knows what to do,” added Laughren, “It needs to fulfill its mandate commitments to ensure healthy fisheries, using an ecosystem-based approach that prioritizes the long-term health of the ocean. Specifically, this includes implementing strong Fisheries Act regulations that require quality rebuilding plans with timelines and targets for rebuilding.”
Oceana Canada is asking Canadians to call on the government this World Oceans Day to step up to protect our oceans and our economy by signing its petition before the government’s Blue Economy Strategy submission deadline of June 15, 2021.
Oceana Canada was established as an independent charity in 2015 and is part of the largest international advocacy group dedicated solely to ocean conservation. Oceana Canada has successfully campaigned to end the shark fin trade, make rebuilding depleted fish populations the law, improve the way fisheries are managed and protect marine habitat. We work with civil society, academics, fishers, Indigenous Peoples and the federal government to return Canada’s formerly vibrant oceans to health and abundance. By restoring Canada’s oceans, we can strengthen our communities, reap greater economic and nutritional benefits and protect our future.
EOSERA Informs on Benefits of Nasal Rinsing with New Product: NOSE WELL™
Backed by science, EOSERA educates on the advantages of nasal rinsing. EOSERA’s newest product, NOSE WELL™, is a gravity-fed device used to rinse out the sinus cavities, treating symptoms like congestion.
Fort Worth, TX, June 8th, 2021 - Studies show that rinsing the nasal passages may offer a variety of benefits, including improving sinus-related quality of life. Doctors recommend that anyone with allergies or sinus congestion use a nasal rinse like NOSE WELL to help rapidly clear the nose of allergens and debris. There are no known serious side effects and rinsing the nasal passages can even reduce the amount of medication patients with sinusitis routinely take[1].In addition to helping reduce the symptoms of seasonal allergies and sinus congestion, clinical studies show that nasal rinsing devices can also help reduce nasal discomfort and may relieve symptoms of sinus pressure or infections[2]. However, only around 4% of people in the U.S. use a nasal rinse to help manage their allergy, cold, and flu symptoms[3]. NOSE WELL is here to help you breathe easier by removing discomfort and inconvenience from nasal care.EOSERA’S NOSE WELL Nasal Rinsing System uses innovative, gravity-fed technology to make your nasal rinsing process comfortable, easy, and efficient. NOSE WELL rinses your sinuses with a push of a button and eliminates awkward rinsing positions and cumbersome neti pots with its slim, sleek design and ergonomic features. Including 25 premixed packets that mix with distilled water, an ergonomically shaped bottle, and two nozzles (1 slow-flow, 1 regular flow) you have all you need to care for your nose. NOSE WELL Nasal Rinsing System will be available on www.MyNoseWell.com and Amazon in May 2021. How to use NOSE WELL™ Nasal Rinsing System[1] Rabago D et al. Efficacy of daily hypertonic saline nasal irrigation among patients with sinusitis: A randomized controlled trial. The Journal of Family Practice. 2002 Dec; 51(12): 1049-1055.[2] Papsin B, McTavish A. Saline nasal irrigation Its role as an adjunct treatment. Canadian Family Physician. 2003 Feb; 49: 168-173.[3] Succar et al., International Forum of Allergy & Rhinology, 2019 NOSE WELL: when being nosey isn’t a bad thing“NOSE WELL Nasal Rinsing System offers a unique rinsing experience. We tried and tested many types of nasal rinsing devices before developing what we think is revolutionary for the nasal category,” says CEO, Elyse Dickerson. EOSERA hit it right on the nose with NOSE WELLAbout EOSERAEOSERA®, Inc. is a multi-million-dollar, female-led biotech company committed to developing innovative products that address underserved healthcare needs.
CORRECTING and REPLACING - On World Oceans Day, Oceana Canada calls on Feds to Put Wild Fish First in Developing a Blue Economy Strategy
Only ¼ of our Fisheries are Healthy; 97% of Canadians Want the Government to Rebuild Them
TORONTO, June 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Oceana Canada, please note the "petition" link just above the contact section has been updated. The corrected release follows:
On the eve of World Oceans Day, new polling1 released today from Oceana Canada finds that an overwhelming majority of Canadians care deeply about healthy oceans and protecting wild fish populations: 97 per cent say it is important that the Canadian government work to rebuild fish populations to healthy levels, and 95 per cent of all Canadians — 99 per cent of Atlantic Canadians — say it is an important part of our post-pandemic economic recovery.
Canada has not kept pace with progressive fishing nations in correcting the historic mistake of overfishing by allowing fish populations to rebuild, thus creating healthier ecosystems, more jobs, food and income, and opportunities to practice cultural traditions. However, right now, there is a once-in-a-generation opportunity to fix this. Fisheries and Oceans Canada is asking for input before June 15, 2021, to help shape its Blue Economy Strategy that aims to make the oceans healthy and prosperous as part of Canada’s plan to ‘build back better’ from the economic and social havoc wreaked by the global COVID-19 pandemic.
In the face of the global pandemic and environmental threats from climate change, plastic pollution, overfishing and habitat destruction, the need to protect and restore our oceans has never been more urgent. However, most of the historically bountiful wild fish populations we have relied on for food, jobs, income, culture and recreation have been collapsed for decades or are declining due to overfishing and mismanagement. Only a quarter of Canada’s fisheries are healthy.
“The original foundation of Canada’s ‘blue economy’ has always been our most plentiful and naturally renewing resource: wild fish – which today support the largest job, income and revenue-generating sector within Canada’s ocean-based economy,” said Josh Laughren, Executive Director, Oceana Canada. “Rebuilding fish to healthy, abundant levels must be central to any blue economy strategy, for our oceans and for all the people that rely on them.”
“For Prime Minister Justin Trudeau and Fisheries Minister Bernadette Jordan, this is a once-in-a-generation opportunity. Canada can be a leader with a regenerative blue economy strategy that is the envy of the world, but only if it prioritizes our oceans’ most renewable resource. Without wild fish, there is no blue economy,” said Laughren. “We urge the many Canadians who care so passionately about this issue to join us and call on the government to deliver on its promise to rebuild Canada’s once world-class fisheries, which we have systematically depleted over the past century, for the sake of all those who rely on it today and as a moral obligation to future generations,” said Laughren.
“The good news is that the government already knows what to do,” added Laughren, “It needs to fulfill its mandate commitments to ensure healthy fisheries, using an ecosystem-based approach that prioritizes the long-term health of the ocean. Specifically, this includes implementing strong Fisheries Act regulations that require quality rebuilding plans with timelines and targets for rebuilding.”
Oceana Canada is asking Canadians to call on the government this World Oceans Day to step up to protect our oceans and our economy by signing its petition before the government’s Blue Economy Strategy submission deadline of June 15, 2021.
Oceana Canada was established as an independent charity in 2015 and is part of the largest international advocacy group dedicated solely to ocean conservation. Oceana Canada has successfully campaigned to end the shark fin trade, make rebuilding depleted fish populations the law, improve the way fisheries are managed and protect marine habitat. We work with civil society, academics, fishers, Indigenous Peoples and the federal government to return Canada’s formerly vibrant oceans to health and abundance. By restoring Canada’s oceans, we can strengthen our communities, reap greater economic and nutritional benefits and protect our future.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
NOSE WELL: when being nosey isn’t a bad thing“NOSE WELL Nasal Rinsing System offers a unique rinsing experience. We tried and tested many types of nasal rinsing devices before developing what we think is revolutionary for the nasal category,” says CEO, 
EOSERA hit it right on the nose with NOSE WELLAbout EOSERA